ReviewESC heart failure2021
Levosimendan-induced venodilation is mediated by opening of potassium channels.
Review in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Clinical efficacy and hemodynamic effects of levosimendan in cardiac surgery patients after surgery.Journal of cardiothoracic surgery · 2025Trial
- Levosimendan ameliorates cardiomyocyte injury and mitochondrial dysfunction in an Nrf2-dependent manner in mice with sepsis-induced cardiomyopathy.Acta biochimica et biophysica Sinica · 2025Article
- Levosimendan: A New Therapeutical Strategy in Patients with Renal Insufficiency.Cardiovascular drugs and therapy · 2025Review
- Serum interleukin-6, tumour necrosis factor-a, D-dimer after recombinant human brain natriuretic peptide combined with levosimendan in patients with heart failure.Journal of medical biochemistry · 2025Article
- Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?Journal of clinical medicine · 2024Article
- What Do We Know about Peripartum Cardiomyopathy? Yesterday, Today, Tomorrow.International journal of molecular sciences · 2024Review
- Levosimendan Reverses Cardiac Malfunction and Cardiomyocyte Ferroptosis During Heart Failure with Preserved Ejection Fraction via Connexin 43 Signaling Activation.Cardiovascular drugs and therapy · 2024Article
- A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.European journal of heart failure · 2024Article
- Levosimendan for sepsis-induced myocardial dysfunction: friend or foe?Frontiers in cardiovascular medicine · 2024Review
- OR-1896 increases force of contraction in the isolated human atrium.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Use of Levosimendan in Patients with Advanced Heart Failure: An Update.Journal of clinical medicine · 2022Review
- Hydrogen Sulfide-Induced Vasodilation: The Involvement of Vascular Potassium Channels.Frontiers in pharmacology · 2022Review
- Levosimendan-induced venodilation is mediated by opening of potassium channels.ESC heart failure · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unique vascular responses adhere to the cardiovascular efficacy of the inodilator levosimendan. In particular, selective venodilation appears to explain its clinical benefit during pulmonary hypertension complicated by heart failure with preserved ejection fraction. Vasodilators increase vessel diameter in various parts of the vascular system to different degrees and thereby influence blood pressure, its distribution, and organ perfusion depending on their mechanisms of action. Levosimendan and its long-lived active metabolite OR-1896 mobilize a set of vasodilatory mechanisms, that is, the opening of the ATP-sensitive K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.